Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A SHR-1210 BE Study on Healthy Subjects
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05799183
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Safety and Effectiveness of Trappa Ethanolamine Tablets Combined With Ciclosporin in the Treatment of Primary Treatment of Non-severe Aplastic Anemia
Phase 2
Recruiting
- Conditions
- Non-severe Aplastic Anemia
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT05797623
- Locations
- 🇨🇳
Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.
Phase 1
Not yet recruiting
- Conditions
- HER2 Low Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-03-31
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT05792410
A Phase I Clinical Study of the Safety， Tolerability，Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05781048
HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer
Phase 3
Recruiting
- Conditions
- First-line Treatment of Advanced Pancreatic Cancer
- Interventions
- Drug: HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 778
- Registration Number
- NCT05751850
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject
Phase 1
Completed
- Conditions
- Diabetes
- Interventions
- Drug: NovoRapid®；HR011408 injection
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT05737576
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects
Phase 1
Recruiting
- Conditions
- Diabetes
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05719961
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: INS068 injection
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 423
- Registration Number
- NCT05702073
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 513
- Registration Number
- NCT05699408
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 117
- Registration Number
- NCT05685420
© Copyright 2025. All Rights Reserved by MedPath